Asprosin in Behect Patients

August 31, 2026 updated by: Eman Ahmed Ibrahim Hasan, Assiut University

Asprosin as a Potential Biomarker for Disease Activity in Behcet Disease

This study aims to investigate serum Asprosin concentrations in patients with BD and their relationship with disease activity and major clinical manifestations.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Behçet's disease (BD) is a chronic, recurrent, multisystem inflammatory vasculitis characterized by various systemic manifestations involving all vessel sizes in both the arterial and venous systems [1,2].

Given that BD is a prototypical systemic vasculitis in which endothelial damage and vascular inflammation are central pathogenic mechanisms, the identification of novel biomarkers reflecting vascular involvement is of major clinical importance[3].

Asprosin is an adipokine that beyond its metabolic effects, carries growing evidence suggesting its associated with vascular pathologies [4].

Experimental and clinical studies have demonstrated that Asprosin contributes to endothelial dysfunction, induces phenotypic switching in vascular smooth muscle cells, and facilitates vascular remodeling by activating pro-inflammatory signaling pathways such as TLR4-NF-κB-NLRP3 [4,5]. Furthermore, Asprosin has been implicated in endothelial-to-mesenchymal transition through TGF-β signaling, thereby exacerbating peripheral arterial disease and vascular stiffness[4,5]. Although endothelial dysfunction and surrogate markers of vascular injury (e.g., impaired flow-mediated dilation, increased intima-media thickness, oxidative stress markers) have been extensively studied in BD[3], the role of Asprosin in this disease remains unexplored.

In this context, Asprosin may represent a link between metabolic pathways and immune mediated vascular inflammation, warranting investigation in systemic vasculitis as potential biomarkers of disease activity [6].

Study Type

Observational

Enrollment (Estimated)

44

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Samar Hasanein Goma, MD
  • Phone Number: 01061828586

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study will include adult patients with Behçet's disease fulfilling the International Criteria for Behçet's Disease (ICBD), as well as age- and sex-matched healthy controls. Patients will be recruited from the Rheumatology Department. The study will assess serum Asprosin levels in relation to disease activity in Behçet's disease.

Description

Inclusion Criteria:

  • Adult subjects (≥ 18 years) satisfying the International Criteria for Behçet's Disease (ICBD) will be included in [7].

Exclusion Criteria:

  • Patients with other autoimmune diseases.
  • Patients with Acute inflammatory condition at the time of blood sampling.
  • Pregnant participants, and participants with active infection, known malignancy, diabetes mellitus, chronic kidney or liver disease, thyroid or other endocrine disorders, obesity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of asprosin level in behcet disease and its association with disease activity
Time Frame: Baseline
To investigate serum asprosin level in behcet disease
Baseline
Assessment of asprosin level in behcet disease and its association with disease activity
Time Frame: Baseline assessment at the time of enrollment
To investigate serum Asprosin concentrations in patients with BD.
Baseline assessment at the time of enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Director: Marwa Ahmed Abdel- aziz Galal, MD, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

October 30, 2027

Study Registration Dates

First Submitted

August 31, 2026

First Submitted That Met QC Criteria

August 31, 2026

First Posted (Actual)

September 3, 2026

Study Record Updates

Last Update Posted (Actual)

September 3, 2026

Last Update Submitted That Met QC Criteria

August 31, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Asprosin in behcet patients

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe